Facial RejuvenationNCT07753564
Unipolar Radiofrequency Treatment Combined With SkinCeuticals A.G.E. Ultra Cream for Facial Rejuvenation
A study of Facial Rejuvenation, run by Beijing Artemis Medical Beauty Clinic at 1 site in China.
Trial summary
To evaluate the efficacy and safety of monopolar radiofrequency treatment combined with SkinCeuticals A.G.E. Ultra Cream for facial rejuvenation Read more about this study
- Who is it for?
- Ages 30 to 60 years, women only
- Conditions the study is for
- Facial Rejuvenation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteChina
- Study dates
- 29 May 2026to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 60 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Female, aged 30-60 years;
- Fine lines on both sides of the forehead meet Grade 1-5 according to the Skin Aging Atlas;
- Crow's feet on both sides meet Grade 2-5 according to the Skin Aging Atlas;
- Perioral wrinkles on both sides meet Grade 1-7 or nasolabial folds on both sides meet Grade 1-6 according to the Skin Aging Atlas;
- Lower facial laxity and sagging meet Grade 1-5 according to the Skin Aging Atlas;
- Subjects with consistent skin condition on both sides of the face who are scheduled to receive unipolar radiofrequency treatment;
Show all 9Show fewer
- Able to comply well with the study requirements and maintain a regular lifestyle throughout the study period;
- Able to read and understand all contents of the informed consent form and voluntarily sign the ICF;
- Agree not to use any cosmetics, medications, or health supplements that may affect the study results during the trial period.
Who cannot join
- Allergic constitution or history of severe allergies (e.g., immediate hypersensitivity symptoms, allergic dermatitis);
- Presence of facial skin diseases (including severe freckles, atopic dermatitis, psoriasis, acute eczema, severe acne, etc.), skin infections (including viral, bacterial, fungal), or skin masses of unknown nature;
- Presence of large areas of birthmarks, scratch marks, vitiligo, pigmented nevi, keloids, or other skin manifestations on the face that may affect the evaluation;
- Presence of implantable electronic devices in the body (e.g., pacemaker, implantable cardioverter-defibrillator);
- Diagnosed with serious clinical conditions such as endocrine diseases, immune system diseases, severe organ failure, or malignant tumors;
- Diagnosed with severe mental illness or cognitive dysfunction, deemed by the investigator as unable to complete the evaluation or questionnaires involved in the study;
Show all 15Show fewer
- Received or planned to receive facial radiofrequency or botulinum toxin treatment within 6 months prior to enrollment or during the study;
- Received chemotherapy or systemic corticosteroids within 3 months prior to enrollment;
- Received or planned to receive facial photoelectric treatments (e.g., laser, intense pulsed light), fillers (e.g., sodium hyaluronate, collagen), thread lifts, or other aesthetic procedures within 3 months prior to enrollment or during the study;
- Received or planned to receive facial mesotherapy or chemical peeling within 1 month prior to enrollment or during the study;
- Used cosmetics, skincare products, or topical medications with firming or anti-wrinkle claims (e.g., glycolic acid, salicylic acid, mandelic acid, tretinoin, hydroquinone, azelaic acid, adapalene, etc.) on the face within 14 days prior to enrollment;
- Other conditions that, in the investigator's judgment, render the subject unsuitable for unipolar radiofrequency treatment;
- Pregnant or breastfeeding women;
- Participated in other interventional clinical trials within 1 month prior to enrollment;
- Other circumstances under which the investigator considers the subject should not participate in this clinical trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Beijing Artemis Medical Beauty Clinic
Beijing, Beijing Municipality
Xiaoge Ma, +86 010-65666810, 1621525631@qq.com
Lanping Pu
About this study
Official title: A Prospective, Single-center, Single-blind, Randomized Split-face Controlled Clinical Study Evaluating the Efficacy and Safety of Unipolar Radiofrequency Treatment Combined With SkinCeuticals A.G.E. Ultra Cream for Facial Rejuvenation
To evaluate the efficacy and safety of monopolar radiofrequency treatment combined with SkinCeuticals A.G.E. Ultra Cream for facial rejuvenation
Read the detailed description
Facial aging is a multidimensional process that progresses with age, involving the synergistic degenerative changes of the skin, soft tissues, and skeletal structure. Its typical features include skin laxity, deepening of fine lines and wrinkles, rough texture, and dull complexion. Among these, the loss of collagen and elastin in the dermis is considered the core mechanism underlying reduced skin firmness and the formation of fine lines. Collagen loss is generally caused by a combination of intrinsic and extrinsic factors. Intrinsically, as age increases, the function of fibroblasts in the skin gradually declines, reducing their capacity to synthesize collagen, which leads to thinning of the dermis and decreased skin elasticity, manifesting as roughness and laxity. In addition, glycation plays a significant role in skin aging. Under a high-glucose environment, advanced glycation end products (AGEs) are prone to form in the skin, which stiffen the collagen structure, reduce elasticity, and impair repair capacity. AGEs further compromise fibroblast function, decreasing collagen production while increasing its degradation, ultimately exacerbating skin laxity and wrinkle formation . Among extrinsic factors, chronic ultraviolet exposure is a major accelerator of skin aging. Ultraviolet radiation induces oxidative damage and inflammatory responses in the skin, promoting collagen degradation while inhibiting its synthesis, thereby significantly accelerating the aging process. Under the combined influence of these factors, skin hydration and barrier function progressively decline, clinically presenting as uneven skin tone, reduced radiance, and accelerated aging. In terms of visual appearance, skin aging is mainly characterized by deepened wrinkles, decreased firmness, and increased laxity, particularly pronounced in the forehead, periorbital area, perioral region, and facial contour. These aging manifestations, marked by wrinkle formation and skin laxity, highlight the necessity of improving skin firmness and contour through medical aesthetic interventions, and further demonstrate the value of monopolar radiofrequency treatment in facial rejuvenation.
Monopolar radiofrequency (i.e., Thermage®), as a non-invasive anti-aging technology, delivers radiofrequency energy to the dermis, causing immediate contraction of collagen fibers and stimulating fibroblasts to promote subsequent collagen neogenesis, thereby improving skin firmness, contour laxity, and fine lines. A substantial body of literature indicates that monopolar radiofrequency treatment produces stable and reproducible clinical outcomes in terms of facial tightening, tissue lifting, and improvement of superficial wrinkles, with a favorable safety profile, making it one of the most widely used skin anti-aging radiofrequency devices. However, although radiofrequency treatment can achieve collagen remodeling, its effects on the skin barrier, radiance, and deep AGEs are limited. Therefore, combining radiofrequency treatment with skincare products that possess anti-glycation, reparative, and collagen-promoting properties may further enhance facial rejuvenation outcomes.
Currently, there is no unified, systematic clinical pathway for comprehensive skin management following non-invasive energy-based medical aesthetic procedures such as radiofrequency and focused ultrasound. To address this clinical need, SkinCeuticals has taken the lead in recent years in proposing the concept of "holistic skincare" and has formulated the Chinese Clinical Practice Expert Consensus on Peri-Procedural Holistic Skincare for Non-Invasive Energy-Based Medical Aesthetic Procedures. According to the consensus, holistic skincare refers to the systematic integration of functional skincare products into the skin management workflow during the peri-procedural period of non-invasive energy-based aesthetic treatments, covering the phases before treatment, immediately after treatment, and subsequent home maintenance. The expert consensus notes that while energy-based treatments such as radiofrequency improve skin firmness, they may also affect the skin barrier to some extent and are accompanied by oxidative, glycative, and inflammatory responses, making targeted skincare intervention necessary for comprehensive management. SkinCeuticals A.G.E. Ultra Cream, as a key component of the holistic skincare framework, is formulated around glycation-related aging pathways, covering multiple key dimensions including anti-glycation, promotion of multiple types of collagen production, and support of skin barrier stability. The flavonoid components and dipotassium glycyrrhizate in its compound anti-glycation concentrate help mitigate glycation effects, reduce collagen glycation damage, and block AGE formation pathways, thereby lowering the risk of collagen structural and functional deterioration. Meanwhile, ingredients such as pro-xylane solution, rhamnose, and Gentiana lutea root extract in the formula help support fibroblast activity and participate in the synthesis and tissue remodeling of key structural proteins including type IV, type VII, and type XVII collagen. This contributes to improving skin firmness while maintaining skin barrier stability and overall skin condition. Existing clinical studies have shown that SkinCeuticals A.G.E. Ultra Cream can effectively reduce facial wrinkles, improve skin elasticity, and ameliorate sagging manifestations, providing scientific evidence for comprehensive skin management following non-invasive energy-based aesthetic treatments. Based on the above mechanisms of skin aging and the characteristics of holistic skincare, this study adopts a combined intervention model of monopolar radiofrequency treatment plus SkinCeuticals A.G.E. Ultra Cream, incorporating both subjective efficacy indicators and skin physiological parameters to validate the efficacy and synergistic effects of SkinCeuticals A.G.E. Ultra Cream, thereby providing cutting-edge clinical evidence for the concept of holistic skincare.
- Conditions
- Facial Rejuvenation
- Being tested
- Left face A.G.E+Right face control, Right face A.G.E+Left face control
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Left face A.G.E+Right face controlOther
The left side of the face serves as the experimental side, and the right side serves as the control side. The experimental side uses SkinCeuticals A.G.E. Ultra Cream, while the control side uses a standard cream.
Right face A.G.E+Left face controlOther
The left side of the face serves as the control side, and the right side serves as the experimental side. The experimental side uses SkinCeuticals A.G.E. Ultra Cream, while the control side uses a standard cream.
| Study group | Role | What they receive |
|---|---|---|
| Left face A.G.E+Right face control | Other | The left side of the face serves as the experimental side, and the right side serves as the control side. The experimental side uses SkinCeuticals A.G.E. Ultra Cream, while the control side uses a standard cream. Receives: Other: Left face A.G.E+Right face control |
| Right face A.G.E+Left face control | Other | The left side of the face serves as the control side, and the right side serves as the experimental side. The experimental side uses SkinCeuticals A.G.E. Ultra Cream, while the control side uses a standard cream. Receives: Other: Right face A.G.E+Left face control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Investigator Global Aesthetic Improvement Scale (GAIS) assessment at 12 weeks post-treatment
The blinded evaluator will assess subjects using the Global Aesthetic Improvement Scale (GAIS). The scale contains two questions: 1. Global aesthetic improvement - left side, and 2. Global aesthetic improvement - right side. Each question is rated on a 5-level scale: Level 1 = Very marked improvement, Level 2 = Marked improvement, Level 3 = Somewhat improved, Level 4 = No change, and Level 5 = Worse than before. The minimum value is 1 per item, and the maximum value is 5 per item. A lower score indicates a better outcome, meaning higher scores represent a worse outcome.
Measured: 12 weeks (±7 days) post-treatment
Secondary outcomes (13)
Global Aesthetic Improvement Scale (GAIS) assessment
The blinded evaluator will assess subjects using the Global Aesthetic Improvement Scale (GAIS). The scale contains two questions: 1. Global aesthetic improvement - left side, and 2. Global aesthetic improvement - right side. Each question is rated on a 5-level scale: Level 1 = Very marked improvement, Level 2 = Marked improvement, Level 3 = Somewhat improved, Level 4 = No change, and Level 5 = Worse than before. The minimum value is 1 per item, and the maximum value is 5 per item. A lower score indicates a better outcome, meaning higher scores represent a worse outcome.
Measured: 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment
Patient satisfaction with treatment
The assessment uses a Subject Satisfaction Questionnaire. The questionnaire contains 5 identical questions to be evaluated separately for the left and right sides of the face. The 5 questions are:
- Satisfaction with the overall skin care effects of the Thermage procedure.
- Overall improvement in facial wrinkles after using the product.
- Improvement in facial skin elasticity after using the product.
- Improvement in facial skin plumpness after using the product.
- Improvement in skin hydration after using the product.
Each question is rated on a 5-level scale, with scores as follows:
- point - Very Dissatisfied
- points - Dissatisfied
- points - Neutral / Average
- points - Satisfied
- points - Very Satisfied
Higher Score Means: Better outcome (higher satisfaction)
Measured: 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment
Improvement in skin elasticity and firmness
The investigator will assess the skin on both sides of the face using the CK Skin Analyzer with a Cutometer probe; a single measurement will be taken
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in transepidermal water loss
The investigator will assess transepidermal water loss on both sides of the face using the CK Skin Analyzer with a Vapometer probe. Measurements will be taken twice, and the average value will be used as the final result.
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in skin hydration
The investigator will assess transepidermal water loss on both sides of the face using the CK Skin Analyzer with a moisture content probe. Measurements will be taken three times, and the average value will be used as the final result.
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in skin glossiness
The investigator will assess skin glossiness on both sides of the face using the CK Skin Analyzer with a Glossymeter probe. Measurements will be taken three times, and the average value will be used as the final result.
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in dermal thickness and density
The investigator will assess the thickness and density of both sides of the face using a skin ultrasound device; a single measurement will be taken.
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in the number and volume of nasolabial folds
The investigator will assess the number and volume of wrinkles on both sides of the face nasolabial folds using the Antera 3D imaging system.
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in jowl volume
The investigator will assess the jowl area on both sides of the face using the Antera 3D imaging system.
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Area percentage of nasolabial folds, crow's feet, and marionette lines
The investigator will assess the area percentage of wrinkles at three sites on both sides of the face (crow's feet, nasolabial folds, and marionette lines) using the VISIA Skin Analysis System.
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in skin AGEs
The investigator will assess the AGEs index on both sides of the face using the AGE Reader; a single measurement will be taken.The indicator measured by the AGE Reader is typically expressed in AU (Arbitrary Units) and reflects the accumulation level of Advanced Glycation End Products (AGEs) in skin tissue. AGEs are the products of non-enzymatic reactions between proteins or lipids and sugars. A lower value generally indicates less accumulation of AGEs, suggesting a better metabolic state, lower levels of oxidative stress and glycation reactions, and a relatively lower risk of skin aging.
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in the number and volume of crow's feet
The investigator will assess the number and volume of wrinkles on both sides of the face crow's feet using the Antera 3D imaging system.
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in the number and volume of marionette lines
The investigator will assess the number and volume of wrinkles on both sides of the face marionette lines using the Antera 3D imaging system.
Measured: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2026
- Study start29 May 2026
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Facial RejuvenationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Artemis Medical Beauty Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07753564
- Sponsor's protocol ID
- 21536062511
- Status last verified
- Aug 2026
- First submitted
- 22 Jul 2026
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Single-center, Single-blind, Randomized Split-face Controlled Clinical Study Evaluating the Efficacy and Safety of Unipolar Radiofrequency Treatment Combined With SkinCeuticals A.G.E. Ultra Cream for Facial Rejuvenation
- ClinicalTrials.gov ID
- NCT07753564
- Acronym / sponsor ID
- 21536062511
- Conditions
- Facial Rejuvenation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Beijing Artemis Medical Beauty ClinicUniversity, hospital or other
- Study start
- 29 May 2026 (actual)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 7 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the efficacy and safety of monopolar radiofrequency treatment combined with SkinCeuticals A.G.E. Ultra Cream for facial rejuvenation
Detailed description
Facial aging is a multidimensional process that progresses with age, involving the synergistic degenerative changes of the skin, soft tissues, and skeletal structure. Its typical features include skin laxity, deepening of fine lines and wrinkles, rough texture, and dull complexion. Among these, the loss of collagen and elastin in the dermis is considered the core mechanism underlying reduced skin firmness and the formation of fine lines. Collagen loss is generally caused by a combination of intrinsic and extrinsic factors. Intrinsically, as age increases, the function of fibroblasts in the skin gradually declines, reducing their capacity to synthesize collagen, which leads to thinning of the dermis and decreased skin elasticity, manifesting as roughness and laxity. In addition, glycation plays a significant role in skin aging. Under a high-glucose environment, advanced glycation end products (AGEs) are prone to form in the skin, which stiffen the collagen structure, reduce elasticity, and impair repair capacity. AGEs further compromise fibroblast function, decreasing collagen production while increasing its degradation, ultimately exacerbating skin laxity and wrinkle formation . Among extrinsic factors, chronic ultraviolet exposure is a major accelerator of skin aging. Ultraviolet radiation induces oxidative damage and inflammatory responses in the skin, promoting collagen degradation while inhibiting its synthesis, thereby significantly accelerating the aging process. Under the combined influence of these factors, skin hydration and barrier function progressively decline, clinically presenting as uneven skin tone, reduced radiance, and accelerated aging. In terms of visual appearance, skin aging is mainly characterized by deepened wrinkles, decreased firmness, and increased laxity, particularly pronounced in the forehead, periorbital area, perioral region, and facial contour. These aging manifestations, marked by wrinkle formation and skin laxity, highlight the necessity of improving skin firmness and contour through medical aesthetic interventions, and further demonstrate the value of monopolar radiofrequency treatment in facial rejuvenation.
Monopolar radiofrequency (i.e., Thermage®), as a non-invasive anti-aging technology, delivers radiofrequency energy to the dermis, causing immediate contraction of collagen fibers and stimulating fibroblasts to promote subsequent collagen neogenesis, thereby improving skin firmness, contour laxity, and fine lines. A substantial body of literature indicates that monopolar radiofrequency treatment produces stable and reproducible clinical outcomes in terms of facial tightening, tissue lifting, and improvement of superficial wrinkles, with a favorable safety profile, making it one of the most widely used skin anti-aging radiofrequency devices. However, although radiofrequency treatment can achieve collagen remodeling, its effects on the skin barrier, radiance, and deep AGEs are limited. Therefore, combining radiofrequency treatment with skincare products that possess anti-glycation, reparative, and collagen-promoting properties may further enhance facial rejuvenation outcomes.
Currently, there is no unified, systematic clinical pathway for comprehensive skin management following non-invasive energy-based medical aesthetic procedures such as radiofrequency and focused ultrasound. To address this clinical need, SkinCeuticals has taken the lead in recent years in proposing the concept of "holistic skincare" and has formulated the Chinese Clinical Practice Expert Consensus on Peri-Procedural Holistic Skincare for Non-Invasive Energy-Based Medical Aesthetic Procedures. According to the consensus, holistic skincare refers to the systematic integration of functional skincare products into the skin management workflow during the peri-procedural period of non-invasive energy-based aesthetic treatments, covering the phases before treatment, immediately after treatment, and subsequent home maintenance. The expert consensus notes that while energy-based treatments such as radiofrequency improve skin firmness, they may also affect the skin barrier to some extent and are accompanied by oxidative, glycative, and inflammatory responses, making targeted skincare intervention necessary for comprehensive management. SkinCeuticals A.G.E. Ultra Cream, as a key component of the holistic skincare framework, is formulated around glycation-related aging pathways, covering multiple key dimensions including anti-glycation, promotion of multiple types of collagen production, and support of skin barrier stability. The flavonoid components and dipotassium glycyrrhizate in its compound anti-glycation concentrate help mitigate glycation effects, reduce collagen glycation damage, and block AGE formation pathways, thereby lowering the risk of collagen structural and functional deterioration. Meanwhile, ingredients such as pro-xylane solution, rhamnose, and Gentiana lutea root extract in the formula help support fibroblast activity and participate in the synthesis and tissue remodeling of key structural proteins including type IV, type VII, and type XVII collagen. This contributes to improving skin firmness while maintaining skin barrier stability and overall skin condition. Existing clinical studies have shown that SkinCeuticals A.G.E. Ultra Cream can effectively reduce facial wrinkles, improve skin elasticity, and ameliorate sagging manifestations, providing scientific evidence for comprehensive skin management following non-invasive energy-based aesthetic treatments. Based on the above mechanisms of skin aging and the characteristics of holistic skincare, this study adopts a combined intervention model of monopolar radiofrequency treatment plus SkinCeuticals A.G.E. Ultra Cream, incorporating both subjective efficacy indicators and skin physiological parameters to validate the efficacy and synergistic effects of SkinCeuticals A.G.E. Ultra Cream, thereby providing cutting-edge clinical evidence for the concept of holistic skincare.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Left face A.G.E+Right face control | Other | Other: Left face A.G.E+Right face controlThe left side of the face serves as the experimental side, and the right side serves as the control side. The experimental side uses SkinCeuticals A.G.E. Ultra Cream, while the control side uses a standard cream. |
| Right face A.G.E+Left face control | Other | Other: Right face A.G.E+Left face controlThe left side of the face serves as the control side, and the right side serves as the experimental side. The experimental side uses SkinCeuticals A.G.E. Ultra Cream, while the control side uses a standard cream. |
Who may qualify
- Ages
- 30 to 60 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Female, aged 30-60 years;
- Fine lines on both sides of the forehead meet Grade 1-5 according to the Skin Aging Atlas;
- Crow's feet on both sides meet Grade 2-5 according to the Skin Aging Atlas;
- Perioral wrinkles on both sides meet Grade 1-7 or nasolabial folds on both sides meet Grade 1-6 according to the Skin Aging Atlas;
- Lower facial laxity and sagging meet Grade 1-5 according to the Skin Aging Atlas;
Key exclusion criteria (15 listed)
- Allergic constitution or history of severe allergies (e.g., immediate hypersensitivity symptoms, allergic dermatitis);
- Presence of facial skin diseases (including severe freckles, atopic dermatitis, psoriasis, acute eczema, severe acne, etc.), skin infections (including viral, bacterial, fungal), or skin masses of unknown nature;
- Presence of large areas of birthmarks, scratch marks, vitiligo, pigmented nevi, keloids, or other skin manifestations on the face that may affect the evaluation;
- Presence of implantable electronic devices in the body (e.g., pacemaker, implantable cardioverter-defibrillator);
- Diagnosed with serious clinical conditions such as endocrine diseases, immune system diseases, severe organ failure, or malignant tumors;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Left face A.G.E+Right face controlThe left side of the face serves as the experimental side, and the right side serves as the control side. The experimental side uses SkinCeuticals A.G.E. Ultra Cream, while the control side uses a standard cream. | Other | Left face A.G.E+Right face control |
| Right face A.G.E+Left face controlThe left side of the face serves as the control side, and the right side serves as the experimental side. The experimental side uses SkinCeuticals A.G.E. Ultra Cream, while the control side uses a standard cream. | Other | Right face A.G.E+Left face control |
Primary outcome
Investigator Global Aesthetic Improvement Scale (GAIS) assessment at 12 weeks post-treatment
Time frame: 12 weeks (±7 days) post-treatment
The blinded evaluator will assess subjects using the Global Aesthetic Improvement Scale (GAIS). The scale contains two questions: 1. Global aesthetic improvement - left side, and 2. Global aesthetic improvement - right side. Each question is rated on a 5-level scale: Level 1 = Very marked improvement, Level 2 = Marked improvement, Level 3 = Somewhat improved, Level 4 = No change, and Level 5 = Worse than before. The minimum value is 1 per item, and the maximum value is 5 per item. A lower score indicates a better outcome, meaning higher scores represent a worse outcome.
13 secondary outcomes
Global Aesthetic Improvement Scale (GAIS) assessment
Time frame: 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment
Patient satisfaction with treatment
Time frame: 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment
Improvement in skin elasticity and firmness
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in transepidermal water loss
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in skin hydration
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in skin glossiness
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in dermal thickness and density
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in the number and volume of nasolabial folds
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in jowl volume
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Area percentage of nasolabial folds, crow's feet, and marionette lines
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in skin AGEs
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in the number and volume of crow's feet
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Improvement in the number and volume of marionette lines
Time frame: Screening period, 1 week (±2 days) post-treatment, 2 weeks (±2 days) post-treatment, 4 weeks (±7 days) post-treatment, 8 weeks (±7 days) post-treatment, 12 weeks (±7 days) post-treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Facial Rejuvenation
Recruiting
Ultraformer MPT Combined With Fractional CO2 Versus Fractional CO2 Alone for Facial Rejuvenation
Skin Aging
RecruitingPhase 4
PLLA and CaHA-R for Aesthetic Rejuvenation
Aesthetic
Not yet recruitingPhase 3
Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality
Skin Aging, Facial Aging
Not yet recruiting
Evaluation of SofWave Sofware-Guided Energy Delivery for Lower Face and Neck Rejuvenation
Facial Wrinkles, Jawline Contour
RecruitingEarly Phase 1
Secretome Treatment for Facial Rejuvenation
Facial Aging, Rejuvenation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Facial Rejuvenation, run by Beijing Artemis Medical Beauty Clinic at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiaoge Ma (+86 010-65666810, 1621525631@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Investigator Global Aesthetic Improvement Scale (GAIS) assessment at 12 weeks post-treatment (time frame: 12 weeks (±7 days) post-treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026; AzTrials last refreshed its copy on 8 Nov 2026.